Trinity Biotech

Trinity Biotech Goodwill

The Goodwill of Trinity Biotech (TRIB) as of Nov 11, 2026 is 13.97 M USD. In the previous year, Goodwill was 13.84 M USD — a change of 0.92% (higher).

Goodwill

13.97 MUSD

YoY

0.92%

Last updated:

Goodwill of Trinity Biotech is 2025 13.97 M USD. Goodwill of Trinity Biotech was 2024 13.84 M USD. It decreases by 0.92% higher compared to the previous year.

The Trinity Biotech Goodwill history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Goodwill
Date
Goodwill
Jan 1, 2018
16.14 M USD
Jan 1, 2019
12.59 M USD
Jan 1, 2020
12.59 M USD
Jan 1, 2021
12.54 M USD
Jan 1, 2022
12.54 M USD
Jan 1, 2023
0.00 USD
Jan 1, 2024
13.84 M USD
Jan 1, 2025
13.97 M USD
The Trinity Biotech Goodwill history
YEARGoodwillYoY
13.97 MUSD+0.92%
13.84 MUSD—
0.00USD-100.00%
12.54 MUSD0.00%
12.54 MUSD-0.43%
12.59 MUSD0.00%
12.59 MUSD-21.99%
16.14 MUSD-9.82%
17.90 MUSD-30.56%
25.77 MUSD-51.08%
52.69 MUSD-0.79%
53.11 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Goodwill of Trinity Biotech is 13.97 M USD in 2025.

Goodwill of Trinity Biotech changed from 13.84 M USD to 13.97 M USD, representing a 0.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Goodwill Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

Goodwill is the premium paid above fair market value in an acquisition. It represents intangible value such as brand recognition, customer relationships, and intellectual property.

Goodwill's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill's Trinity Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Trinity Biotech

All Key Metrics — Trinity Biotech